Meeting
2023 ASCO Annual Meeting
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
Authors
Julia Piasecki
Bristol Myers Squibb, Princeton, NJ
Julia Piasecki , Keyur Desai , Carolyn Courtney , Ethan Thompson , Jim Pratt , Noopur S. Raje , Krina K. Patel , Marc S. Raab , Mark Cook , Katy L. Simonsen , Mihaela Popa McKiver , Shari Kaiser , Nathan Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03651128
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8031)
DOI
10.1200/JCO.2023.41.16_suppl.8031
Abstract #
8031
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2021 ASCO Annual Meeting
Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
First Author: Salomon Manier
Poster
2022 ASCO Annual Meeting
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
First Author: Andrzej J. Jakubowiak
Poster
2021 ASCO Annual Meeting
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
First Author: Larry D. Anderson, Jr